ALS breakthrough: Ashwagandha-derived drug shows promise in slowing progression of amyotrophic lateral sclerosis

ALS breakthrough: Ashwagandha-derived drug shows promise in slowing progression of amyotrophic lateral sclerosis

Every year roughly 1,000 Canadians are diagnosed with amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease). Some 4,000 Canadians are currently living with the disease. There are few effective treatments available to slow the progression of ALS and, unfortunately, most sufferers die within two to five years of being diagnosed. As neuroscience researchers, we are dedicated to finding ways to reduce the symptoms of ALS. In this a…

IPL344 slows ALS progression in trial, data suggest

Daily treatment with IPL344 for up to three years was safe and appeared to slow amyotrophic lateral sclerosis (ALS) progression, according to recently published data from a small Phase 2a clinical trial. Patients undergoing treatment gained weight and experienced slower declines in functional abilities and lung function. The treatment also lengthened survival in patients, compared with external placebo groups. The majority of patients tolerated …